【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人 (除非用於思覺失調、雙極症、或化療止吐)。

思覺失調症 Schizophrenia

Selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist
Low doses of amisulpride may improve negative symptoms in schizophrenic patients, while high doses (equal to or greater than 600 mg/day) have anti-dopaminergic activity making it beneficial for treating positive psychotic symptoms related to schizophrenia or acute delusional attacks.

Absolute bioavailability is 48%. Plasma protein binding is low (16%). Metabolism is limited, with most of a dose appearing in the urine as unchanged drug. The elimination half-life is approximately 12 hours after oral administration.

1. Known hypersensitivity to amisulpride
2. Pheochromocytoma
3. Prolactin-dependent tumor
4. Children below 15 years of age
5. Pregnancy, lactation
6. Concomitant use with drugs which may induce torsade de pointes:
(1) Class IA Antiarrhythmics (Quinidine, Disopyramide)
(2) Class III Antiarrhythmics (Amiodarone, Sotalol)
7. Concomitant use with Levodopa
8. Severe renal impairment (CrCl< 10mL/min)

Use of the drug is not recommended during pregnancy unless the benefits justify the potential risks.

An alternate drug may be preferred, especially while nursing a newborn or preterm infant. Some reviewers consider amisulpride to be contraindicated during breastfeeding.

Insomnia, anxiety, agitation, extrapyramidal symptoms (tremor, hypertonia, hypersalivation, akathisia, hypokinesia), daytime drowsiness

Mainly negative symptoms:
50-300 mg/day, normally 100mg/day
Positive and negative symptoms:
400-800 mg/day
Acute Schizophrenia:
Initial 400-800 mg/day, do not exceed 1200 mg/day

Avoid use in children under 15 years of age.

1. CrCl >60 mL/min: No adjustment required
2. CrCl 30-60 mL/min: Decrease dose by 1/2
3. CrCl 30-60 mL/min: Decrease dose by 1/3
4. CrCl <10 mL/min: : Avoid use

No adjustment required